(Q35879344)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Cancer vaccine development: on the way to break immune tolerance to malignant cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Simone Mocellin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Donato Nitti

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 October 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

Experimental Cell Research

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

267-278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunoediting: from immunosurveillance to tumor escape

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A fresh look at tumor immunosurveillance and immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

T-cell clones that react against autologous human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Viruses, cancer and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Post-transplant malignancy: the role of immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Progress in human tumour immunology and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumors as elusive targets of T-cell-based active immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cytokines and immune response in the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Adjuvant immunotherapy for solid tumors: from promise to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

B7-mediated costimulation and the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CD28/B7 system of T cell costimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Short-term kinetics of tumor antigen expression in response to vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

7 January 2021

The dual role of IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Telomeres, telomerase, and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Molecular interactions mediating T cell antigen recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Functional diversity of helper T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The central role of CD4(+) T cells in the antitumor immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The role of CD4+ T cell responses in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CD4 T cells and their role in antitumor immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CD22 as a target of passive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

7 January 2021

IL-13 effector functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Role of nitric oxide in cancer biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Nitric oxide and the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cancer immunotherapy with natural killer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Oxygen radical-induced natural killer cell dysfunction: role of myeloperoxidase and regulation by serotonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tolerogenic dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Regulatory T cells in autoimmmunity*.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

T-cell regulation by CD28 and CTLA-4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Two isoforms of otubain 1 regulate T cell anergy via GRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tolerance, DCs and tryptophan: much ado about IDO

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

IDO and tolerance to tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Natural killer cells and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The innate immune response to tumors and its role in the induction of T-cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Natural killer cells and dendritic cells: rendezvous in abused tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Strategies for designing and optimizing new generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immunological concepts of vaccine adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Danger signals: SOS to the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Active-specific immunotherapy for melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CpG DNA: security code for host defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Toll-like receptors control activation of adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immunotherapy of human cancer: lessons from mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

CD91: a receptor for heat shock protein gp96

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cytokines as a link between innate and adaptive antitumor immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cytokines in cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dendritic cell immunotherapy: mapping the way.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

GM-CSF-secreting melanoma vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The use of dendritic cells in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dendritic cells in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dendritic cells: a journey from laboratory to clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Signalling pathways of the TNF superfamily: a double-edged sword

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Priming of naive T cells inside tumors leads to eradication of established tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Induction of antitumor immunity by indomethacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Tolerance, danger, and the extended family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Macrophage deactivation by interleukin 10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Histamine in cancer immunotherapy: a preclinical background.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Current uses of isolated limb perfusion in the clinic and a model system for new strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Quantitating cellular immune responses to cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Functional heterogeneity of vaccine-induced CD8(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2004.06.017

10.1016/J.YEXCR.2004.06.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15350526%20AND%20SRC:MED&resulttype=core&format=json

release_ggfnlmsiirdffgslwi47cfbnym

1 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ggfnlmsiirdffgslwi47cfbnym

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference